Clinical and regulatory intelligence for Urothelial Carcinoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

Dabogratinib →

Relevant companies

No related entities indexed yet.

Recent signals(1)

ClinicalJuly 5, 2026

Tyra Biosciences initiates Phase 2A/B trial of Dabogratinib for Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences is conducting Phase 2A/B trial to evaluate the efficacy and safety of Dabogratinib in patients with Low Grade Upper Tract Urothelial Carcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Oncology →

Urothelial Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.